广东医学2017，Vol.38Issue(1)：38-41,4.
贝伐珠单抗治疗复发恶性脑胶质瘤36例临床分析
Bevacizumab in the treatment of recurrent malignant gliomas: a report of 36 cases
杨群英 1郭琤琤 1林富华 1陈银生 1张继 1陈正和 1王翦 1赛克 1牟永告1
作者信息
- 1. 中山大学肿瘤防治中心神经外科/神经肿瘤科、华南肿瘤学国家重点实验室、癌症医学协同创新中心 广东广州510060
- 折叠
摘要
Abstract
Objective To evaluate the effect and adverse reaction of bevacizumab in the treatment of recurrent malignant gliomas .Methods This study retrospectively analyzed the clinical data and outcomes of 36 patients with re-current malignant gliomas who had tumor progression after surgery combined with radiation and temozolomide treatment . Response Assessment in Neuro -Oncology Working Group ( RANO) Criteria was used to evaluate the objective response . Kaplan-Meier method was used to analyze survival .Common Terminology Criteria for Adverse Events v 3.0 was used to e-valuate the adverse events .Results An overall response rate of 58.3%was obtained in the 36 cases.The median pro-gression-free survival (PFS) and overall survival (OS) were 4 months and 7 months, respectively.Main adverse events were hypertension , hepatic functional lesion and marrow depression .Severe adverse events such as intracranial hemorrha-ges, thrombus or gastrointestinal perforation were not observed .Conclusion Bevacizumab is effective and may improve the survival in the patients of recurrent malignant gliomas with tolerant toxicities .关键词
神经胶质瘤/贝伐珠单抗/化学疗法/分子靶向药物治疗Key words
glioma/bevacizumab/chemotherapy/molecule targeted drug treatment引用本文复制引用
杨群英,郭琤琤,林富华,陈银生,张继,陈正和,王翦,赛克,牟永告..贝伐珠单抗治疗复发恶性脑胶质瘤36例临床分析[J].广东医学,2017,38(1):38-41,4.
